Fighting HIV

Fighting HIV

Merck will pay Chimerix $17.5 million on top of royalties on future sales and milestone payments of up to $151 million, according to both companies on Tuesday.

Go back to reading “Merck licenses HIV compound from RTP-based Chimerix”

LTW Partners

Techwire Inside Partners